Akari Therapeutics

Ver el organigrama con sus 12 ejecutivos principales

Biografías más buscadas en Akari Therapeutics

• Rachelle Jacques, President and Chief Executive Officer
• Samir Patel, Director
• Ray Prudo, Executive Chairman of the Board

Recientes movimientos de ejecutivos en Akari Therapeutics

• Samir Patel, se ha incorporado a la empresa como Director  (noticia publicada el 4 de diciembre de 2023).
• Beth-Anne Lang, se ha incorporado a la empresa como Senior Vice President, Regulatory Affairs  (noticia publicada el 3 de agosto de 2023).

Crear su alerta
para seguir los movimientos de los ejecutivos en Akari Therapeutics.

Akari Therapeutics tiene 2.279 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y Adaptive Phage Therapeutics (Estados Unidos).

Popular M&A news in Biotecnología

• Metsera acaba de anunciar una recaudación de fondos de 290 millones de dólares. (publicado el 23 de abril de 2024).
• Histogen has filed for bankruptcy protection  (publicado el 19 de abril de 2024).
• Bruker has announced the acquisition of NanoString Technologies  (publicado el 18 de abril de 2024).

Otros contactos sugeridos en el sector Biotecnología

• Ali Behbahani - Non-Executive Director en Adaptimmune Therapeutics
• Vik Bajaj - Director en Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board en Sensorion

Saber más sobre el sector Biotecnología >

Últimos comunicados de prensa de Akari Therapeutics

• Akari Therapeutics Narrows Pipeline Focus | Akari Therapeutics
• Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy | Akari Therapeutics
• Press Releases | Akari Therapeutics
• Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress | Akari Therapeutics
• Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) | Akari Therapeuti
• Press Releases | Akari Therapeutics
• Akari Therapeutics Announces the Appointment of Accomplished Biotech Executive Melissa Bradford-Klug as Chief Operating Officer to Lead Business Development and Company Growth Strategies | Akari Therapeutics
• Akari Therapeutics Presents Results from the CASCADE and CORONET Studies in COVID-19 at the American Thoracic Society (ATS) 2022 Annual Meeting | Akari Therapeutics
• Akari Therapeutics Reports Full Year 2021 Financial Results and Highlights Clinical Progress | Akari Therapeutics
• Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting | Akari Therapeutics
• View more press releases Close

Redes sociales sobre Akari Therapeutics

• Akari Therapeutics en Wikipedia, Google News y Yahoo Finance
• Akari Therapeutics en LinkedIn, Twitter y YouTube

Contactar a través de e-mail con sus ejecutivos Ray Prudo

Llame a Akari Therapeutics al +1 646...

Ver el organigrama

Register to receive your alert

Señalar un error